PUBLISHER: Renub Research | PRODUCT CODE: 1045894
PUBLISHER: Renub Research | PRODUCT CODE: 1045894
In recent years, lung cancer screening has enabled the detection of lung cancer before symptoms begin. Besides, the main aim of lung cancer screening is to detect lung cancer at its earliest and most treatable stage. Collectively, screening tests involve lab tests that monitor blood and other fluids, genetic tests that study for inherited genetic markers associated with illness, and imaging exams that produce pictures of the inside of the body. In addition, in lung cancer screening, individuals who have a high risk of developing lung cancer but no signs or symptoms of the disease undergo low-dose computed tomography (LDCT) scanning of the chest. According to the Renub Research estimates, Lung Cancer Screening Market is projected to reach US$ 16.7 Billion by 2027.
Globally, these screening is typically available to the general population. However, an individual's needs for a specific screening test are based on age, gender, and family history. Consequently, the lung cancer screening industry is thriving owing to the surge in the incidence of lung cancer due to the rising smoking population, technological progressions in screening, and expanding government support for the early detection of incidents. Moreover, strategic collaborations and renewed recommendations and guidelines on screening are also likely to surge the market growth in the coming years.
The evolution of the pandemic initially influenced the screening programs globally, particularly in the developed countries, owing to travel constraints and lockdowns imposed by governments. This commenced a decline in the number of people screened for this type of cancer. However, the resumption of services during the latter stages of Q2 and H2 2020 led to an expansion in the number of patients screened. This boost compensated for the decline in patients during H1 2020.
Nonetheless, the market is projected to display actual growth post-COVID-19 due to the escalation in demand for imaging solutions as non-essential operations and consultations were forced to be rescheduled when the general mortality ratio settled down. Further, these increase the need for screening and analytical equipment such as MRI, X-ray machinery, and automated tomography systems. The Global Lung Cancer Screening Industry will grow with a nominal CAGR of 1.4% during 2021-2027.
Based on cancer type, the global lung cancer screening industry is segmented into non-small cell lung cancer (NSCLC) and small cell lung cancer. As per our analysis, the non-small cell lung cancer (NSCLC) segment constitutes the highest market share worldwide throughout the period studied. The dominant market share is driven by the deepening awareness about screening in developed and developing countries coupled with the growing cases of NSCLC across the globe.
For instance, as per the American Cancer Society, overall, about 84% of all lung cancers are non-small cell, and 13% are SCLC, as published in January 2021. Contrarily, the small cell lung cancer segment is also expected to capture a growing market share during the forecast period. Further, the surge in the expanding prevalence consolidated with the mounting initiatives by government and non-profit organizations towards initial screening and diagnosis are anticipated to support the small cell lung cancer segment.
Based on end-user, the market is classified into Hospitals & Clinics, Diagnostic Centers and Research institutes. The increasing inclination of patients towards hospitals for cancer screening, the rising number of hospitals in emerging countries, and the strong network of hospitals in the developed countries create a scenario making the hospitals & clinics ranking number one during the forecast period.
Additionally, the growing awareness among the general society, and the growing number of screening applications in healthcare facilities, are also prone to promote the lung cancer screening market growth in the forecasted years. Moreover, the diagnostic centres' segment is expected to capture a comparatively higher market share associated with the expanding collaborations between healthcare providers & payers with diagnostic facilities to offer screening programs and the rising number of diagnostic centres in developed countries worldwide.
Our report covers the United States, Canada, Norway, Italy, France, Germany, United Kingdom, Russia, Spain, China, India, Japan, and South Korea Lung Cancer Screening Industry. Lung cancer is the most common screened cancer and the leading cause of cancer-related deaths in China. During the past years, the incidence and mortality of lung cancer in China have been increasing rapidly. Consistent with the change in developed provinces, adenocarcinoma has become China's most predominant histological sub-type of lung cancer. Targeted therapy became increasingly important in treating most advanced non-small-cell lung cancer (NSCLC) patients, especially patients with adenocarcinoma.
Similarly, India ranks second in the overall market share for lung cancer screening. Despite variation in incidence geographically, lung cancer is leading cancer in many cancer registries in India. Along with an overall increase in screening incidence, rapid growth amongst non-smokers and women is noticed. The patients seen in the younger and younger age group are also multiplying the market share. While smoking remains the primary cause, extremely high air pollution levels are a possible contributory factor for the exponential rise in the incidence of lung cancer screening in the Non-smoking population.
The global market is strengthened with key players, including Illumina, Inc., Abbott Laboratories, Thermo Fisher Scientific, Inc, QIAGEN N.V. and Roche Holding AG. These players hold a vital share in the global lung cancer screening industry. These companies' dominance is associated with the strong distribution network, robust product portfolio of screening devices, mergers and acquisitions, and launching of new products in the market.
For instance, In September 2020, Illumina acquired GRAIL, a healthcare company working in multi-cancer early apprehension, for approximately USD 8 Billion. The purchase will also combine the company's latest product, Galleri multi-cancer screening test.
In September 2021, the FDA approved Thermo Fisher Scientific's Oncomine Dx Target Test as an NGS companion diagnostic for EXKIVITY to distinguish NSCLC patients with EGFR Exon20 insertions. NGS testing is crucial for these patients, as it can facilitate more accurate diagnoses than polymerase chain reaction (PCR) testing, which detects less than 50% of EGFR Exon20 insertions.
Renub Research latest report "Lung Cancer Screening Market, Global Forecast By Cancer Type (Small-cell Lung Cancer Diagnostics and Non-Small-cell Lung Cancer Diagnostics), End-User (Hospitals & Clinics, Diagnostic Centers, Research Institute and Others), Country (United States, Canada, Norway, Italy, France, Germany, United Kingdom, Russia, Spain, China, India, Japan and South Korea), Companies (Illumina, Inc., Abbott Laboratories, Thermo Fisher Scientific, Inc, QIAGEN N.V. and Roche Holding AG)" provides a detailed analysis of Lung Cancer Screening Industry.